Last checked at 2 Mar 2022 07:00
genedrive plc
("genedrive" or the "Company")
Further re Directorate Change
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, confirms that Matthew Fowler, the Group's Chief Financial Officer, will be leaving the Company and stepping down from the Board on 19 April 2022. This follows the announcement on 16 November 2021 that Matthew Fowler intended to stand down after five years in the role, in order to take up a position as Chief Financial Officer of musicMagpie plc.
The Company will make a futher announcement in due course with regards to recruitment of a new Chief Financial Officer.
For further details please contact:
genedrive plc | ||
David Budd: CEO | +44 (0)161 989 0245 | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 | |
James Steel | ||
finnCap (Joint Broker) | +44 (0)20 7220 0500 | |
Geoff Nash / Kate Bannatyne / Alice Lane | ||
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, a high throughput SARS-CoV-2 assay and a test to help in the prevention of hearing loss caused by certain antibiotics in neonates. The Company recently released a point of care test for Covid-19.